Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Anna, Nordenskjöld"'
Autor:
Helena Fohlin, Anna Nordenskjöld, Johan Rosell, Mårten Fernö, Tommy Fornander, Lisa Rydén, Lambert Skoog, Bo Nordenskjöld, Olle Stål
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Hormone receptor positivity predicts benefit from endocrine therapy but the knowledge about the long-term survival of patients with different tumor receptor levels is limited. In this study, we describe the 25 years outcome of tamoxifen (
Externí odkaz:
https://doaj.org/article/70fb0a9414d446158f65dbae4436b48e
Autor:
Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld
Publikováno v:
Breast, Vol 71, Iss , Pp 63-68 (2023)
Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material and methods: We studied 30 years outcome of 4124 postmenopausal patients who were ra
Externí odkaz:
https://doaj.org/article/487528a90ae34cc4bee6e74d37bc5e34
Autor:
Annelie, Johansson, Huma, Dar, Laura J, van 't Veer, Nicholas P, Tobin, Gizeh, Perez-Tenorio, Anna, Nordenskjöld, Ulla, Johansson, Johan, Hartman, Lambert, Skoog, Christina, Yau, Christopher C, Benz, Laura J, Esserman, Olle, Stål, Bo, Nordenskjöld, Tommy, Fornander, Linda S, Lindström
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(35)
To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer.Secondary analysis of the Stockholm trial (STO-5, 1990-1997) randomly assigning 924 premenopausal patients to 2 years of goserelin (3.6 mg subcut
Autor:
Oscar Danielsson, Huma Dar, Gizeh Perez-Tenorio, Anna Nordenskjöld, Christina Yau, Christopher C. Benz, Laura J. Esserman, Bo Nordenskjöld, Olle Stål, Tommy Fornander, Annelie Johansson, Linda S. Lindström
Publikováno v:
Cancer Research. 83:P3-05
Background: Women with estrogen receptor (ER)-positive disease have a long-term risk of distant recurrence. The poor survival of premenopausal women diagnosed with breast cancer combined with the otherwise long life expectancy makes it especially imp
Autor:
Annelie Johansson, Huma Dar, Anna Nordenskjöld, Gizeh Perez-Tenorio, Christina Yau, Christopher C. Benz, Laura J. Esserman, Laura Van’t Veer, Bo Nordenskjöld, Olle Stål, Tommy Fornander, Linda S. Lindström
Publikováno v:
Cancer Research. 83:P2-03
Background: Tamoxifen is a standard endocrine therapy for both pre- and postmenopausal ER-positive breast cancer patients. Patients with ER-positive disease have a long-term risk of distant recurrence, thus, long-term follow-up studies are essential
Autor:
Huma Dar, Annelie Johansson, Anna Nordenskjöld, Gizeh Perez-Tenorio, Christina Yau, Christopher C. Benz, Laura J. Esserman, Bo Nordenskjöld, Olle Stål, Tommy Fornander, Linda S. Lindström
Publikováno v:
Cancer Research. 83:P2-03
Background: The risk for patients with estrogen receptor (ER)-positive breast cancer remains stable decades after primary diagnosis, with a large proportion of distant metastatic events occurring late. Thus, long-term follow-up studies are essential
Autor:
Huma, Dar, Annelie, Johansson, Anna, Nordenskjöld, Adina, Iftimi, Christina, Yau, Gizeh, Perez-Tenorio, Christopher, Benz, Bo, Nordenskjöld, Olle, Stål, Laura J, Esserman, Tommy, Fornander, Linda S, Lindström
Publikováno v:
JAMA network open. 4(6)
Clinically used breast cancer markers, such as tumor size, tumor grade, progesterone receptor (PR) status, and Ki-67 status, are known to be associated with short-term survival, but the association of these markers with long-term (25-year) survival i
Autor:
Swedish western, Per Karlsson, Zakaria Einbeigi, Helena Fohlin, Chaido Chamalidou, L-G Arnesson, Bo Nordenskjöld, Erik Holmberg, Anna Nordenskjöld, Per Albertsson, Barbro Linderholm
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 59, Iss, Pp 294-300 (2021)
Breast, Vol 59, Iss, Pp 294-300 (2021)
Background Invasive lobular carcinoma (ILC) comprises 8–15 % of all invasive breast cancers and large population-based studies with >10 years of follow-up are rare. Whether ILC has a long-time prognosis different from that of invasive ductal carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e6661cbf8615db2a58b65ec5865251
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-179613
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-179613
Autor:
LJ Esserman, Christina Yau, Anna Nordenskjöld, Anna L.V. Johansson, Gizeh Pérez-Tenorio, Huma Dar, Tommy Fornander, Olle Stål, L. Van ‘T Veer, Linda S. Lindström, Bo Nordenskjöld, Christopher C. Benz
Publikováno v:
Annals of Oncology. 32:S21
Autor:
Anna Nordenskjöld, Per Albertsson, Helena Fohlin, Lars-Gunnar Arnesson, Per Karlsson, Zakaria Einbeigi, Erik Holmberg
Publikováno v:
Acta oncologica (Stockholm, Sweden). 58(1)
During the recent decades, breast cancer survival has gradually improved but there is limited knowledge on the improvement in population-based studies of patients diagnosed with different stages of the disease and in different age groups.In two Swedi